Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
3.660
-0.420 (-10.28%)
Nov 21, 2024, 11:59 AM EST - Market open
Tango Therapeutics Employees
Tango Therapeutics had 140 employees as of December 31, 2023. The number of employees increased by 30 or 27.27% compared to the previous year.
Employees
140
Change (1Y)
30
Growth (1Y)
27.27%
Revenue / Employee
$309,879
Profits / Employee
-$881,393
Market Cap
393.15M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 140 | 30 | 27.27% |
Dec 31, 2022 | 110 | 19 | 20.88% |
Dec 31, 2021 | 91 | 14 | 18.18% |
Dec 31, 2020 | 77 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Sonida Senior Living | 3,955 |
Health Catalyst | 1,300 |
National Research | 435 |
Arcturus Therapeutics Holdings | 180 |
Acelyrin | 135 |
Foghorn Therapeutics | 116 |
Korro Bio | 102 |
Aura Biosciences | 89 |
TNGX News
- 15 days ago - Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights - Business Wire
- 15 days ago - Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program - Business Wire
- 2 months ago - Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data - Seeking Alpha
- 3 months ago - Tango Therapeutics to Participate in Upcoming Investor Conferences - Business Wire
- 3 months ago - Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights - Business Wire
- 6 months ago - Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference - Business Wire
- 6 months ago - Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program - PRNewsWire
- 6 months ago - Tango Therapeutics to stop development of cancer therapy - Reuters